Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Dyadic International Inc DYAI

Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.


NDAQ:DYAI - Post by User

Post by averagepennieson Feb 01, 2024 10:32am
47 Views
Post# 35856968

Dyadic to Attend BIO CEO & Investor Conference and European

Dyadic to Attend BIO CEO & Investor Conference and European

JUPITER, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be attending the following events during the month of February 2024.

DIAH-Discovery to Innovation in Animal Health
Hotel NH Gent Belfort, Belgium
February 6 – 8, 2024

The Annual Meat Evolution Leaders Summit #MEVO
Hyatt Regency Barcelona Tower, Spain
February 7 – 8, 2024

BIO CEO & Investor Conference
The New York Marriott Marquis, New York
February 26 – 27, 2024    

If you would like to schedule a meeting with one of our management members at any of these events, please contact Heidi Zosiak at hzosiak@dyadic.com.

 

https://www.globenewswire.com/news-release/2024/02/01/2821988/0/en/Dyadic-to-Attend-BIO-CEO-Investor-Conference-and-European-Industry-Events.html

<< Previous
Bullboard Posts
Next >>